Literature DB >> 26554366

The risk of suicide after clozapine discontinuation: Cause for concern.

Kathleen M Patchan1, Charles Richardson, Gopal Vyas, Deanna L Kelly.   

Abstract

BACKGROUND: Clozapine is a second-generation antipsychotic that has been shown to reduce suicidal ideation and suicidal behaviors in patients with schizophrenia. However, it is underutilized because of its serious side effects.
METHODS: We describe 3 patients with a history of suicide ideation and attempts who were successfully treated and maintained in the community without suicidal tendencies while taking clozapine. All 3 patients, men in their 20s, discontinued clozapine because of side effects and subsequently committed suicide. We also review the literature on clozapine's effects on suicidality.
RESULTS: In these 3 cases, suicide followed abrupt discontinuation of clozapine or transition to another antipsychotic.
CONCLUSIONS: This case series is the first of its kind to document the risk of suicide when clozapine is discontinued. The decision to discontinue clozapine should be made carefully, especially because clozapine is considered the treatment of last resort for patients with treatment-resistant schizophrenia and suicidal ideation. We stress the importance of minimizing the risk of abrupt clozapine discontinuation and recommend further evaluation of suicide ideation and attempts when clozapine is discontinued.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26554366      PMCID: PMC5470314     

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  21 in total

1.  What is the clinical significance of the discontinuation syndrome seen with clozapine?

Authors:  A J Goudie
Journal:  J Psychopharmacol       Date:  2000-06       Impact factor: 4.153

2.  Clozapine underutilization and discontinuation in African Americans due to leucopenia.

Authors:  Deanna L Kelly; Julie Kreyenbuhl; Lisa Dixon; Raymond C Love; Deborah Medoff; Robert R Conley
Journal:  Schizophr Bull       Date:  2006-12-14       Impact factor: 9.306

3.  Clozapine utilization and outcomes by race in a public mental health system: 1994-2000.

Authors:  Deanna L Kelly; Lisa B Dixon; Julie A Kreyenbuhl; Deborah Medoff; Anthony F Lehman; Raymond C Love; Clayton H Brown; Robert R Conley
Journal:  J Clin Psychiatry       Date:  2006-09       Impact factor: 4.384

4.  Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group.

Authors:  G D Tollefson; M A Dellva; C A Mattler; J M Kane; D A Wirshing; B J Kinon
Journal:  J Clin Psychopharmacol       Date:  1999-10       Impact factor: 3.153

5.  Prolonged psychotic relapse after abrupt clozapine withdrawal.

Authors:  M A Parsa; Y H al-Lahham; L F Ramirez; H Y Meltzer
Journal:  J Clin Psychopharmacol       Date:  1993-04       Impact factor: 3.153

6.  Predictors of clozapine discontinuation in patients with schizophrenia.

Authors:  Amir Krivoy; Liron Malka; Tsvi Fischel; Abraham Weizman; Avi Valevski
Journal:  Int Clin Psychopharmacol       Date:  2011-11       Impact factor: 1.659

7.  Mortality, attempted suicide, re-hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden-a register-based study.

Authors:  Gunilla Ringbäck Weitoft; Mats Berglund; Eva A Lindström; Mikael Nilsson; Peter Salmi; Måns Rosén
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-01-17       Impact factor: 2.890

Review 8.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

9.  Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal.

Authors:  B Ekblom; K Eriksson; L H Lindström
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 10.  Clozapine: a review of clinical practice guidelines and prescribing trends.

Authors:  Stephanie Warnez; Silvia Alessi-Severini
Journal:  BMC Psychiatry       Date:  2014-04-07       Impact factor: 3.630

View more
  4 in total

Review 1.  Clozapine in Reducing Aggression and Violence in Forensic Populations.

Authors:  Kathleen Patchan; Gopal Vyas; Ann L Hackman; Marie Mackowick; Charles M Richardson; Raymond C Love; Ikwunga Wonodi; MacKenzie A Sayer; Matthew Glassman; Stephanie Feldman; Deanna L Kelly
Journal:  Psychiatr Q       Date:  2018-03

Review 2.  [Suicidality in schizophrenic psychosis: a current overview].

Authors:  Roman Knorr; Klaus Hoffmann
Journal:  Nervenarzt       Date:  2020-11-09       Impact factor: 1.214

3.  Perils of Pragmatic Psychiatry: How We Can Do Better.

Authors:  Maju Mathew Koola; Joseph Sebastian
Journal:  HSOA J Psychiatry Depress Anxiety       Date:  2016-02-23

Review 4.  Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19.

Authors:  Ana Miruna Dragoi; Ioana Radulescu; Bogdana Adriana Năsui; Anca Lucia Pop; Valentin Nicolae Varlas; Simona Trifu
Journal:  Brain Sci       Date:  2020-11-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.